Trials / Completed
CompletedNCT02435914
Safety, Efficacy, Tolerability and Pharmacokinetics of AGN-223575 Ophthalmic Suspension in Patients With Dry Eye Disease
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 236 (actual)
- Sponsor
- Allergan · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study will evaluate the safety, efficacy, tolerability, and systemic pharmacokinetics of 3 different doses of topical ophthalmic AGN-223575 suspension compared to AGN-223575 vehicle in patients with dry eye disease.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | AGN-223575 ophthalmic solution | AGN-223575 ophthalmic solution once or twice daily |
| DRUG | AGN-223575 vehicle ophthalmic solution | Vehicle to AGN22375 ophthalmic solution once or twice daily. |
Timeline
- Start date
- 2015-06-01
- Primary completion
- 2016-01-01
- Completion
- 2016-01-01
- First posted
- 2015-05-06
- Last updated
- 2019-04-05
- Results posted
- 2019-04-05
Locations
28 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT02435914. Inclusion in this directory is not an endorsement.